Australia's most trusted
source of pharma news
Friday, 29 March 2024
Posted 11 August 2022 AM
ASX-listed Starpharma has strengthened its partnership with MSD, signing a new 12-month research agreement aimed at enhancing antibody drug conjugates (ADCs) using its drug delivery system.
While ADCs have become an increasingly valuable class of therapeutic agents in oncology and hematology, Starpharma's dendrimer-based drug delivery system called DEP has the potential to overcome limitations of first-generation ADCs.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.